The Roles of Complement Activation vs. Shiga Toxin Binding to Endothelium in eHUS.

eHUS 中补体激活与志贺毒素与内皮细胞结合的作用。

基本信息

批准号：
10323266
负责人：
Eric Franklin Grabowski
金额：
$ 40.82万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-01-01 至 2023-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10323266
关键词：
Acute Affect Alternative Complement Pathway Animals Antibodies Appearance Bacterial Toxins Binding Blood Coagulation Factor Blood Platelets Blood Vessels Blood coagulation Blood donor Blood flow Body Weight decreased Cell Adhesion Molecules Cell surface Cerebrum Cessation of life Characteristics Child Childhood Coagulation Process Complement Complement 3a Complement 3b Complement 3d Complement 5a Complement Activation Complement Factor D Complement Membrane Attack Complex Complex Convection Data Deposition Development Disease Endothelial Cells Endothelium Epidemic Event Factor Xa Failure Fibrin Future Gene Silencing Growth Hematocrit procedure Hemolytic-Uremic Syndrome Human Image Immune Immune system In Vitro Injections Injury to Kidney Kidney Kidney Failure Laboratories Lead Lectin Mannose Binding Lectin Measures Mediating Membrane Membrane Microdomains Messenger RNA Modeling Molecular Mus Neurocognitive Deficit Oxidoreductase P-Selectin Pathogenesis Pathway interactions Phosphatidylserines Plasma Platelet Count measurement Protein Disulfide Isomerase Renal function Role Seizures Serum Shiga Toxin Shiga-Like Toxin I Shiga-Like Toxin II Supportive care Surface System TFPI TLR4 gene TNF gene Thrombin Thromboplastin Thrombus Time Umbilical vein Up-Regulation Vascular Endothelial Cell Video Microscopy Weight Whole Blood Work arteriole base body system brain dysfunction complement C5b-7 complex complement pathway cytokine digital glomerular endothelium humanized mouse in vivo inhibitor monoclonal antibody 3F8 monolayer mouse model new therapeutic target novel oxidation post gamma-globulins preservation receptor response shear stress soluble complement C5b-9 thrombotic von Willebrand Factor

项目摘要

Summary/Abstract Epidemic hemolytic uremic syndrome (eHUS) is a leading cause of acute renal injury and failure in children (65% of cases of eHUS), who may also suffer seizures, neurocognitive deficits from cerebral ischemic events, and other organ system failure. This project will examine the mechanisms whereby Shiga toxin (Stx)-induced complement activation and Stx interaction with the endothelium generate procoagulant tissue factor (TF) activity and platelet adhesion molecules in this thrombotic microangiopathy. We hypothesize that Stx activates the mannose binding lectin-2 (MBL-2) pathway of complement, leading to the binding of the complement effectors C3b, C5, C5b-9, and MBL2 on or near endothelial cell (EC) Gb3, the inducible receptor on ECs for Stx, and on or near toll-like receptor 4 (TLR4). Activation of endothelium via cytokines and Stx follows, with subsequent upregulation of platelet adhesion molecules and expression of EC pro-coagulant tissue factor (TF) activity, leading to the development of eHUS and further thrombin and factor Xa-mediated complement activation. Specific Aims/Hypotheses: 1: To demonstrate that complement activation by Stx leads to C3d, C5a, and MBL-2 binding to ECs and the appearance of membrane-bound C5b-9, with expression of procoagulant TF activity and platelet adhesion molecules (P-selectin, high MW von Willebrand Factor (vWF) multimers). To show that complement is activated via the MBL-2 lectin pathway, and not the alternative pathway. 2: To demonstrate that Stx, complement activation, and upregulated procoagulant TF and platelet adhesion molecules contribute to platelet thrombus formation during flow using an in vitro flow model of eHUS employing monolayers of HUVECs or HGECs. The studies incorporate the effects of shear rate (convection of complement components, clotting factors) characteristic of glomerular arterioles, and shear stress, which are in vivo conditions. 3: To identify the molecular mechanisms of complement activation in a novel humanized MBL-2 mouse model of Stx-2-induced renal injury. This proposal will demonstrate that Stx leads to MBL-2 lectin pathway complement activation, procoagulant EC TF activity, and platelet-fibrin thrombus formation in flowing blood, in vitro and in vivo, thereby providing novel therapeutic targets (i.e., MBL-2 and/or TF) for a devastating disease that presently lacks a definitive therapy. 1

摘要/摘要流行性溶血性尿毒综合征（EHUS）是急性肾损伤和儿童失败的主要原因（65％的EHU病例），他也可能遭受癫痫发作，脑缺血性事件的神经认知缺陷，和其他器官系统故障。该项目将检查Shiga毒素（STX）诱导的机制补体激活和与内皮的STX相互作用产生凝聚组织因子（TF）该血栓性微血管病中的活性和血小板粘附分子。我们假设STX激活补体的甘露糖结合凝集素2（MBL-2）途径，导致补体的结合效应物C3b，C5，C5B-9和MBL2在内皮细胞（EC）GB3上，EC上的诱导受体 STX，以及类似收费的受体4（TLR4）。通过细胞因子和STX激活内皮，随后是随后的血小板粘附分子的上调和EC促凝组织因子（TF）的表达活动，导致EHUS的发展以及进一步的凝血酶和因子XA介导的补体激活。具体目标/假设： 1：证明STX的补体激活导致C3D，C5A和MBL-2与EC结合以及膜结合的C5B-9的出现，表达了Procagulant TF活性和血小板粘附分子（P-选择素，高MW von Willebrand因子（VWF）多聚体）。显示该补体通过MBL-2凝集素途径激活，而不是替代途径。 2：证明STX，补体激活和上调的Procagulant TF和血小板粘附分子使用体外流模型在流动过程中有助于血小板血栓形成雇用HUVEC或HGECS的单层的EHU。研究结合了剪切的影响肾小球动脉的特征（补体组成部分的对流，凝结因子的对流），和剪切应力，是体内条件。 3：确定新型人性化MBL-2中补体激活的分子机制 STX-2诱导的肾损伤的小鼠模型。该建议将表明STX导致MBL-2凝集素途径补体激活，Procagulant EC TF活性和流动血液，体外和体内的血小板 - 纤维蛋白血栓形成，从而提供新颖治疗靶标（即MBL-2和/或TF），用于目前缺乏明确治疗的毁灭性疾病。 1